ASXL1 and CD4+/CD56+ hematodermic neoplasm: From a genomic standpoint, BPDCN is marked by recurrent chromosomal abnormalities (e.g., del(5q), 12p/13q rearrangements, and monosomy 9), as well as frequent mutations in epigenetic regulators such as TET2, ASXL1, and DNMT3A.